Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm?

Hristos Z. Kaimakliotis, M. Francesca Monn, K. Clint Cary, Jose A. Pedrosa, Kevin Rice, Timothy A. Masterson, Thomas A. Gardner, Noah Hahn, Richard S. Foster, Richard Bihrle, Liang Cheng, Michael O. Koch

Research output: Contribution to journalArticle

Abstract

Objectives: Plasmacytoid variant (PCV) urothelial cancer (UC) of the bladder is rare, with poor clinical outcomes. We sought to identify factors that may better inform expectations of tumor behavior and improve management options in patients with PCV UC. Materials and methods: A retrospective analysis of the Indiana University Bladder Cancer Database between January 2008 and June 2013 was performed comparing 30 patients with PCV UC at cystectomy to 278 patients with nonvariant (NV) UC at cystectomy who underwent surgery for muscle-invasive disease. Multivariable logistic regression was used to assess precystectomy variables associated with non-organ-confined disease at cystectomy and Cox regression analysis to assess variables associated with mortality. Results: Patients with PCV UC who were diagnosed with a higher stage at cystectomy (73% pT3-4 vs. 40%, P = 0.001) were more likely to have lymph node involvement (70% vs. 25%, P

Original languageEnglish (US)
Pages (from-to)833-838
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume32
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cystectomy
Neoplasms
Therapeutics
Logistic Models
Lymph Nodes
Regression Analysis
Databases
Muscles
Mortality

Keywords

  • Bladder cancer
  • Cystectomy
  • Plasmacytoid variant
  • Variant histology

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this

Kaimakliotis, H. Z., Monn, M. F., Cary, K. C., Pedrosa, J. A., Rice, K., Masterson, T. A., ... Koch, M. O. (2014). Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm? Urologic Oncology: Seminars and Original Investigations, 32(6), 833-838. https://doi.org/10.1016/j.urolonc.2014.03.008

Plasmacytoid variant urothelial bladder cancer : Is it time to update the treatment paradigm? / Kaimakliotis, Hristos Z.; Monn, M. Francesca; Cary, K. Clint; Pedrosa, Jose A.; Rice, Kevin; Masterson, Timothy A.; Gardner, Thomas A.; Hahn, Noah; Foster, Richard S.; Bihrle, Richard; Cheng, Liang; Koch, Michael O.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 32, No. 6, 2014, p. 833-838.

Research output: Contribution to journalArticle

Kaimakliotis, HZ, Monn, MF, Cary, KC, Pedrosa, JA, Rice, K, Masterson, TA, Gardner, TA, Hahn, N, Foster, RS, Bihrle, R, Cheng, L & Koch, MO 2014, 'Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm?', Urologic Oncology: Seminars and Original Investigations, vol. 32, no. 6, pp. 833-838. https://doi.org/10.1016/j.urolonc.2014.03.008
Kaimakliotis, Hristos Z. ; Monn, M. Francesca ; Cary, K. Clint ; Pedrosa, Jose A. ; Rice, Kevin ; Masterson, Timothy A. ; Gardner, Thomas A. ; Hahn, Noah ; Foster, Richard S. ; Bihrle, Richard ; Cheng, Liang ; Koch, Michael O. / Plasmacytoid variant urothelial bladder cancer : Is it time to update the treatment paradigm?. In: Urologic Oncology: Seminars and Original Investigations. 2014 ; Vol. 32, No. 6. pp. 833-838.
@article{37aa778e5c32408b94356dcbb36e71eb,
title = "Plasmacytoid variant urothelial bladder cancer: Is it time to update the treatment paradigm?",
abstract = "Objectives: Plasmacytoid variant (PCV) urothelial cancer (UC) of the bladder is rare, with poor clinical outcomes. We sought to identify factors that may better inform expectations of tumor behavior and improve management options in patients with PCV UC. Materials and methods: A retrospective analysis of the Indiana University Bladder Cancer Database between January 2008 and June 2013 was performed comparing 30 patients with PCV UC at cystectomy to 278 patients with nonvariant (NV) UC at cystectomy who underwent surgery for muscle-invasive disease. Multivariable logistic regression was used to assess precystectomy variables associated with non-organ-confined disease at cystectomy and Cox regression analysis to assess variables associated with mortality. Results: Patients with PCV UC who were diagnosed with a higher stage at cystectomy (73{\%} pT3-4 vs. 40{\%}, P = 0.001) were more likely to have lymph node involvement (70{\%} vs. 25{\%}, P",
keywords = "Bladder cancer, Cystectomy, Plasmacytoid variant, Variant histology",
author = "Kaimakliotis, {Hristos Z.} and Monn, {M. Francesca} and Cary, {K. Clint} and Pedrosa, {Jose A.} and Kevin Rice and Masterson, {Timothy A.} and Gardner, {Thomas A.} and Noah Hahn and Foster, {Richard S.} and Richard Bihrle and Liang Cheng and Koch, {Michael O.}",
year = "2014",
doi = "10.1016/j.urolonc.2014.03.008",
language = "English (US)",
volume = "32",
pages = "833--838",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Plasmacytoid variant urothelial bladder cancer

T2 - Is it time to update the treatment paradigm?

AU - Kaimakliotis, Hristos Z.

AU - Monn, M. Francesca

AU - Cary, K. Clint

AU - Pedrosa, Jose A.

AU - Rice, Kevin

AU - Masterson, Timothy A.

AU - Gardner, Thomas A.

AU - Hahn, Noah

AU - Foster, Richard S.

AU - Bihrle, Richard

AU - Cheng, Liang

AU - Koch, Michael O.

PY - 2014

Y1 - 2014

N2 - Objectives: Plasmacytoid variant (PCV) urothelial cancer (UC) of the bladder is rare, with poor clinical outcomes. We sought to identify factors that may better inform expectations of tumor behavior and improve management options in patients with PCV UC. Materials and methods: A retrospective analysis of the Indiana University Bladder Cancer Database between January 2008 and June 2013 was performed comparing 30 patients with PCV UC at cystectomy to 278 patients with nonvariant (NV) UC at cystectomy who underwent surgery for muscle-invasive disease. Multivariable logistic regression was used to assess precystectomy variables associated with non-organ-confined disease at cystectomy and Cox regression analysis to assess variables associated with mortality. Results: Patients with PCV UC who were diagnosed with a higher stage at cystectomy (73% pT3-4 vs. 40%, P = 0.001) were more likely to have lymph node involvement (70% vs. 25%, P

AB - Objectives: Plasmacytoid variant (PCV) urothelial cancer (UC) of the bladder is rare, with poor clinical outcomes. We sought to identify factors that may better inform expectations of tumor behavior and improve management options in patients with PCV UC. Materials and methods: A retrospective analysis of the Indiana University Bladder Cancer Database between January 2008 and June 2013 was performed comparing 30 patients with PCV UC at cystectomy to 278 patients with nonvariant (NV) UC at cystectomy who underwent surgery for muscle-invasive disease. Multivariable logistic regression was used to assess precystectomy variables associated with non-organ-confined disease at cystectomy and Cox regression analysis to assess variables associated with mortality. Results: Patients with PCV UC who were diagnosed with a higher stage at cystectomy (73% pT3-4 vs. 40%, P = 0.001) were more likely to have lymph node involvement (70% vs. 25%, P

KW - Bladder cancer

KW - Cystectomy

KW - Plasmacytoid variant

KW - Variant histology

UR - http://www.scopus.com/inward/record.url?scp=84905272956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905272956&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.03.008

DO - 10.1016/j.urolonc.2014.03.008

M3 - Article

C2 - 24954925

AN - SCOPUS:84905272956

VL - 32

SP - 833

EP - 838

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 6

ER -